Ensign Peak Advisors
DFTX

Ensign Peak Advisors’s Definium Therapeutics DFTX Stock Holding History

Ensign Peak Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
466,106
-80,677
-15% -$1.99M 0.04% 306
2026
Q1 		$10.3M Buy
546,783
+284,783
+109% +$4.83M 0.02% 402
2025
Q4 		$3.51M Buy
+262,000
New +$3.24M 0.01% 579

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ensign Peak Advisors's DFTX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Definium Therapeutics (DFTX) stake by 15% in Q2 2026, selling an estimated $1.99M and leaving 466,106 shares worth $21.9M. The position accounts for 0.04% of the portfolio, ranked #306.

Ensign Peak Advisors first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Ensign Peak Advisors held 466,106 shares of Definium Therapeutics worth $21.9M as of Q2 2026.
  • Ensign Peak Advisors sold 80,677 Definium Therapeutics shares in Q2 2026, an estimated $1.99M.
  • Definium Therapeutics made up 0.04% of Ensign Peak Advisors's portfolio in Q2 2026, its #306 holding.
  • Ensign Peak Advisors first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.